MedrivaPeptide Intelligence
Hub Utility

Vendor Evaluation Framework: Evidence Guide (2026)

Hub Utility reference page for Vendor Evaluation Framework: Evidence Guide (2026). Reviewed 2026-06-05.

Statusapproved
TypeReference page
Reviewed2026-06-05
Editorial review: Medriva pages are written by named contributors, reviewed by clinical or subject-matter experts, and updated as evidence or regulatory status changes.

Vendor Evaluation Framework

Quick answer

Vendor Evaluation Framework: Evidence is reviewed as a Medriva hub utility resource. The practical takeaway is to separate what is supported by human evidence from what is still theoretical, commercial, or regulatory-dependent. Evidence grade: n/a. Readers should use this page to frame a clinician conversation, not to self-prescribe, source, dose, or combine peptides.

For current regulatory movement, shortage status, warning letters, and compounding policy, check the Peptide Tracker before relying on older summaries.

A neutral methodology for evaluating compounding pharmacies and research-use-only peptide vendors. We do not publish a vendor scorecard in v1. We publish the framework and link out to public COA databases.

What this page is

A neutral methodology for evaluating compounding pharmacies and research-use-only peptide vendors. We do not publish a vendor scorecard in v1. We publish the framework and link out to public COA databases.

What you'll find here

What this is

A neutral, evidence-based methodology for evaluating compounding pharmacies and research-use-only peptide vendors. We do not publish a vendor scorecard in v1. We publish the framework and link out to public Certificate-of-Analysis (COA) databases.

Why no scorecard

A vendor scorecard invites legal exposure (defamation, tortious interference) and creates perverse incentives (vendors paying for placement, vendors gaming the criteria). The framework is more durable: it teaches the reader to evaluate any vendor themselves.

Framework

1. Regulatory status

  • FDA-registered outsourcing facility (503B)? Verify at the FDA's registered outsourcing facility list.
  • 503A compounding pharmacy? Verify state board of pharmacy licensure.
  • RUO vendor? Verify that the product is labeled "for research use only" and not marketed for human use.

2. Certificate of Analysis (COA)

  • See our COA explainer.
  • Verify HPLC purity ≥ 98%.
  • Verify mass-spec identity matches the expected sequence.
  • Verify endotoxin below USP limit.
  • Verify sterility (where applicable).

3. Third-party testing

  • Verify that the COA is from a third-party lab (not the vendor's own lab).
  • See our third-party lab list.

4. Business practices

  • Clear labeling (concentration, volume, lot number, expiration).
  • Lot-traceable.
  • Documented chain of custody.
  • Responsive to adverse-event reports.

5. Marketing

  • Does the vendor make off-label or efficacy claims? (Red flag.)
  • Does the vendor market RUO product for human use? (Illegal.)
  • Does the vendor disclose all relevant risks?

What to look for, what to reject

  • Look for: clean COA, third-party testing, regulatory status disclosed, transparent business practices.
  • Reject: no COA, vendor's own lab testing, marketing RUO for human use, no lot traceability, unverifiable claims.

Frequently Asked Questions

Can Medriva recommend a specific vendor?

No. We do not endorse specific vendors. Use the framework above.

What if a vendor doesn't provide a COA?

Reject. A vendor who won't provide a COA is selling product that hasn't been independently verified.

Related pages

---

Disclaimer: For informational and educational purposes only. Not medical advice. Medriva does not sell peptides and does not endorse specific vendors.

---

Disclaimer: For informational and educational purposes only. Not medical advice. Always consult a licensed clinician. Medriva does not sell peptides.